Previous 10 | Next 10 |
PTC Therapeutics to Host PTC518 Huntington Disease Deep Dive Webinar PR Newswire SOUTH PLAINFIELD, N.J. , April 7, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webinar in its deep dive series discussing the PTC518 Huntington di...
Potential for 100 gene therapy trials to be using ClearPoint. Expect significant growth in 2H 2021 as elective surgeries rebound and clinical trials restart. Recent expansion to Europe augurs well for European biologics partners. We see potential for $100M+ revenues and 30%+ n...
PTC Therapeutics (PTCT) announces that a $20M milestone payment was triggered by the first commercial sale of Evrysdi (risdiplam) in the European Union under its License and Collaboration Agreement with Roche (RHHBY). Roche is working closely with reimbursement and assessment bodies in Europe...
PTC Therapeutics Announces Commercial Milestone Payment Following the Recent European Approval of Evrysdi™ PR Newswire SOUTH PLAINFIELD, N.J. , April 1, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that a $20 million ...
The European Commission ((EC)) has granted marketing authorization to PTC Therapeutics' (PTCT) Evrysdi (risdiplam) for the treatment of spinal muscular atrophy ((SMA)) in patients 2 months and older.Evrysdi will be for SMA Type 1, 2 or 3 patients with one to four SMN2 copies.The EC approval i...
PTC Therapeutics Announces the European Approval of Evrysdi™ for the Treatment of Spinal Muscular Atrophy - First and only at home treatment approved for SMA - - Proven efficacy in adults and children with SMA 2 months and older - PR Newswire SOUTH PLAIN...
The online health-insurance platform Oscar Health (OSCR) fell more than a tenth on its first day of public trading. With a ~26.2% decline so far since going public early this month, the company had the worst IPO this year among deals valued at least $1B.As the quiet period winds dow...
RBC Capital Markets analyst Brian Abrahams has upgraded shares of PTC Therapeutics (PTCT) from underperform to sector perform and is maintaining his price target at $47.He notes that shares have fallen recently as a result of the March 22 announcement that Roche was stopping dosing in a phase...
Design Therapeutics has filed proposed terms for a $228 million IPO. The firm is developing treatments for Friedreich ataxia and myotonic dystrophy. DSGN is still at a preclinical stage of development and is seeking a high valuation at IPO; the IPO may be more suited to institutio...
Edgewise Therapeutics has filed to raise $150 million in an IPO. The firm is developing treatments for various degenerative neuromuscular diseases. EWTX is operating in a notoriously difficult research area and hasn't provided any Phase 1 initial results, so I'll watch the IPO fro...
News, Short Squeeze, Breakout and More Instantly...
PTC Therapeutics Inc. Company Name:
PTCT Stock Symbol:
NASDAQ Market:
PTC Therapeutics Inc. Website:
PTC Therapeutics Announces Sepiapterin NDA Submission to FDA PR Newswire WARREN, N.J. , July 30, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the sepiapterin NDA to the U.S. FDA. The NDA submission is for the t...
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results PR Newswire WARREN, N.J. , July 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to r...
2024-07-12 10:00:03 ET Jeffrey Hung from Morgan Stanley issued a price target of $32.00 for PTCT on 2024-07-12 08:15:00. The adjusted price target was set to $32.00. At the time of the announcement, PTCT was trading at $33.2. The overall price target consensus is at $43....